B族双鞘肽对晚期肾细胞癌患者的II期试验。

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma.

作者信息

Motzer R, Scher H, Bajorin D, Sternberg C, Bosl G J

机构信息

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

出版信息

Invest New Drugs. 1990 Nov;8(4):391-2. doi: 10.1007/BF00198598.

DOI:10.1007/BF00198598

PMID:2084073

Abstract

Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5%) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell carcinoma.

摘要

23例晚期肾细胞癌患者接受了Didemnin B治疗。21例可评估患者中有1例获得部分缓解（5%）。4例患者出现过敏反应，其中1例为过敏反应。不推荐使用Didemnin B治疗肾细胞癌。